In­fec­tious dis­ease biotech Blue­jay rais­es $182M for he­pati­tis tri­als

Cal­i­for­nia biotech Blue­jay Ther­a­peu­tics has se­cured a megaround to con­tin­ue de­vel­op­ing its treat­ment can­di­dates for chron­ic he­pati­tis D and B.

The $182 mil­lion Se­ries C, dis­closed Thurs­day morn­ing, will bankroll test­ing of sev­en pro­grams, in­clud­ing for­mer No­var­tis and Ex­i­cure as­sets.

The biotech’s lead he­pati­tis as­set, BJT-778, de­rives from No­var­tis and goes against the he­pati­tis B sur­face anti­gen, or HB­sAg, with the goal of eas­ing im­mune cell ex­haus­tion so that the body can con­trol the in­fec­tion. The mon­o­clon­al an­ti­body is in a Phase 1/2 test in Aus­tralia, New Zealand and oth­er coun­tries.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER